Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community.

ABSTRACT:

Importance

The role of amyloid in the progression of Alzheimer disease (AD) pathophysiology is of central interest to the design of randomized clinical trials. The presence of amyloid has become a prerequisite for enrollment in several secondary prevention trials for AD, yet the precise effect of elevated amyloid levels on subsequent clinical and biomarker events is less certain.

Objective

To explore the effect of elevated amyloid levels on subsequent changes in cognition and biomarkers.

Design, setting, and participants

A total of 564 cognitively normal individuals (median age, 78 years) from the Mayo Clinic Study of Aging, a population-based longitudinal study in Olmsted County, Minnesota, with serial cognitive data were selected for this study. The data used in thi

SUBMITTER: Petersen RC 

PROVIDER: S-EPMC4710552 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature